This is one of those I should simply steer clear of.
Critics, on the other hand, point out the teensy problem that the pharmaceutical company’s own drug trials have shown that Addyi (the brand name for flibanserin) doesn’t actually work all that well. The drug, which will likely be available to consumers in mid-October, is a daily medication, and has been associated with some decidedly unsexy side effects, such as dizziness, sleepiness, nausea, insomnia, and dry mouth. Alcohol exacerbates the side effects, so women taking Addyi are told to abstain from drinking as long as they’re taking it. And the payoff is modest at best: In clinical trials involving about 2,400 healthy, pre-menopausal women (their average age was 36), the women taking flibanserin reported up to one more “satisfying sexual event” per month on average, compared with the women who took a placebo.
After all, if ever there is a time to hide behind being … oh, right. Anyway, yeah, it’s after a paragraph like that, something, something, mumble, murmur, I’ll just shut up now.